Shawquia Jackson

Array ( [id] => 20833680 [patent_doc_number] => 20260193183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-07-09 [patent_title] => N,N-DIMETHYLTRYPTAMINE AND RELATED PSYCHEDELICS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 19/555366 [patent_app_country] => US [patent_app_date] => 2026-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19555366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19862257 [patent_doc_number] => 20250101043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => KRAS INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/897646 [patent_app_country] => US [patent_app_date] => 2024-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15902 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18897646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19709222 [patent_doc_number] => 20250019364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 18/883472 [patent_app_country] => US [patent_app_date] => 2024-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 123908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18883472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860667 [patent_doc_number] => 20250099453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS [patent_app_type] => utility [patent_app_number] => 18/821660 [patent_app_country] => US [patent_app_date] => 2024-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18821660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769868 [patent_doc_number] => 20250051294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => METHOD FOR PREPARING CYCLOHEXYL THIAZOLYL PHENYL CARBAMATE [patent_app_type] => utility [patent_app_number] => 18/798938 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21641 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18798938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769869 [patent_doc_number] => 20250051295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => PROCESS FOR THE PREPARATION OF MIRABEGRON FREE FROM GENOTOXIC IMPURITIES [patent_app_type] => utility [patent_app_number] => 18/797055 [patent_app_country] => US [patent_app_date] => 2024-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18797055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875791 [patent_doc_number] => 20250108048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => STING AGONIST COMPOUNDS AND CONJUGATES [patent_app_type] => utility [patent_app_number] => 18/789214 [patent_app_country] => US [patent_app_date] => 2024-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80426 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18789214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769854 [patent_doc_number] => 20250051280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => CRYSTALLINE BIS-MIPROCIN FUMARATE [patent_app_type] => utility [patent_app_number] => 18/781180 [patent_app_country] => US [patent_app_date] => 2024-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18781180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528081 [patent_doc_number] => 20240351983 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => METHODS OF TREATING MOOD DISORDERS [patent_app_type] => utility [patent_app_number] => 18/758102 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18758102 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19707749 [patent_doc_number] => 20250017891 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING CABAZITAXEL PRODRUG-CYCLODEXTRIN INCLUSION COMPLEX, AND APPLICATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 18/755748 [patent_app_country] => US [patent_app_date] => 2024-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 136 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077504 [patent_doc_number] => 12351554 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Crystalline forms of compositions comprising psilocin and psilocybin [patent_app_type] => utility [patent_app_number] => 18/742840 [patent_app_country] => US [patent_app_date] => 2024-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 8686 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18742840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528076 [patent_doc_number] => 20240351978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => METHOD FOR MANUFACTURING AROMATIC NITRILE COMPOUND [patent_app_type] => utility [patent_app_number] => 18/738245 [patent_app_country] => US [patent_app_date] => 2024-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15336 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18738245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20406349 [patent_doc_number] => 20250375458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES [patent_app_type] => utility [patent_app_number] => 18/734622 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 421 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464014 [patent_doc_number] => 20240317683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => METHODS OF TREATING MOOD DISORDERS [patent_app_type] => utility [patent_app_number] => 18/680473 [patent_app_country] => US [patent_app_date] => 2024-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18680473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692745 [patent_doc_number] => 20250011290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => PYRYLIUM METHOD OF PREPARING PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS [patent_app_type] => utility [patent_app_number] => 18/676067 [patent_app_country] => US [patent_app_date] => 2024-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18676067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19600998 [patent_doc_number] => 20240391878 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHOD FOR PREPARING TERT-BUTYL (S)-4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE-1-CARBOXYLATE AND SALTS THEREOF AND ITS USE IN A METHOD FOR PREPARING (S)-4-(1-(2,3-DIMETHYLPHENYL)ETHYL)-1H-IMIDAZOLE AND SALTS THEREOF [patent_app_type] => utility [patent_app_number] => 18/657572 [patent_app_country] => US [patent_app_date] => 2024-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18657572 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19554711 [patent_doc_number] => 20240366503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => CROSSLINKED HYDROGELS WITH ENHANCED RADIOPACITY FOR MEDICAL APPLICATIONS [patent_app_type] => utility [patent_app_number] => 18/653739 [patent_app_country] => US [patent_app_date] => 2024-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18653739 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430897 [patent_doc_number] => 20240299395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => COMBINATION THERAPIES COMPRISING WEE1 INHIBITORS AND DNA DAMAGE RESPONSE (DDR) INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/648164 [patent_app_country] => US [patent_app_date] => 2024-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648164 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20321301 [patent_doc_number] => 20250333389 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => PHARMACEUTICAL FOR THE INHIBITION OF CELLULAR PROTON PUMPS [patent_app_type] => utility [patent_app_number] => 18/647940 [patent_app_country] => US [patent_app_date] => 2024-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19890251 [patent_doc_number] => 20250115563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => MODULATORS OF THE INTEGRATED STRESS PATHWAY [patent_app_type] => utility [patent_app_number] => 18/647747 [patent_app_country] => US [patent_app_date] => 2024-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53197 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18647747 [rel_patent_id] =>[rel_patent_doc_number] =>)